Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 516-522

  Schlosshauer, Peter W ^a   Li, Wei ^a   Lin, Kai Ti ^b   Chan, Joseph L K ^a   Wang, Lu Hai ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Carboplatin; Chemotherapy; Ovarian carcinoma; PI3 kinase; Rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; INSULIN RECEPTOR; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; SH 6; UNCLASSIFIED DRUG;

ANOIKIS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; OVARY TUMOR; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK; TUMOR GROWTH; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHROMONES; DRUG SYNERGISM; FEMALE; HUMANS; MORPHOLINES; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOLS; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 67749123955     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.002     Document Type: Article

References (56)

1. Ozols R.F., Bookman M.A., Connolly D.C., Daly M.B., Godwin A.K., Schilder R.J., et al. Focus on epithelial ovarian cancer. Cancer Cell. 5 (2004) 19-24
2. Sundar S., Symonds R.P., Decatris M.P., Kumar D.M., Osman A., Vasanthan S., et al. Phase II trial of oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol. Oncol. 94 (2004) 502-508
3. Lafky J.M., Wilken J.A., Baron A.T., and Maihle N.J. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophys. Acta 1785 (2008) 232-265
4. Steffensen K.D., Waldstrom M., Andersen R.F., Olsen D.A., Jeppesen U., Knudsen H.J., et al. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int. J. Oncol. 33 (2008) 195-204
5. Ross J.S., Yang F., Kallakury B.V., Sheehan C.E., Ambros R.A., and Muraca P.J. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am. J. Clin. Pathol. 111 (1999) 311-316
6. Zhou B.P., Hu M.C., Miller S.A., Yu Z., Xia W., Lin S.Y., et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J. Biol. Chem. 275 (2000) 8027-8031
7. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64 (2004) 7678-7681
8. Levine D.A., Bogomolniy F., Yee C.J., Lash A., Barakat R.R., Borgen P.I., et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11 (2005) 2875-2878
9. Philp A.J., Campbell I.G., Leet C., Vincan E., Rockman S.P., Whitehead R.H., et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61 (2001) 7426-7429
10. Altomare D.A., Wang H.Q., Skele K.L., De Rienzo A., Klein-Szanto A.J., Godwin A.K., et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23 (2004) 5853-5857
11. Nakayama K., Nakayama N., Kurman R.J., Cope L., Pohl G., Samuels Y., et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther. 5 (2006) 779-785
12. Willner J., Wurz K., Allison K.H., Galic V., Garcia R.L., Goff B.A., et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum. Pathol. 38 (2007) 607-613
13. Kolasa I.K., Rembiszewska A., Janiec-Jankowska A., Dansonka-Mieszkowska A., Lewandowska A.M., Konopka B., et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. relation to TP53, K-RAS and BRCA1 mutations. Gynecol. Oncol. 103 (2006) 692-697
14. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix-Trench G., Thomas E.J., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58 (1998) 2095-2097
15. Alessandro R., and Kohn E.C. Signal transduction targets in invasion. Clin. Exp. Metastasis 19 (2002) 265-273
16. Sachdev P., Jiang Y.X., Li W., Miki T., Maruta H., Nur-E-Kamal M.S., et al. Differential requirement for rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation. J. Biol. Chem. 276 (2001) 26461-26471
17. Nguyen K.T., Wang W.J., Chan J.L., and Wang L.H. Differential requirements of the MAP kinase and PI3 kinase signaling pathways in src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells. Oncogene 19 (2000) 5385-5397
18. Sachdev P., Zeng L., and Wang L.H. Distinct role of phosphatidylinositol 3-kinase and rho family GTPases in Vav3-induced cell transformation, cell motility, and morphological changes. J. Biol. Chem. 277 (2002) 17638-17648
19. Nguyen K.T., Zong C.S., Uttamsingh S., Sachdev P., Bhanot M., Le M.T., et al. The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in ros-induced cell transformation. J. Biol. Chem. 277 (2002) 11107-11115
20. Ellerbroek S.M., Halbleib J.M., Benavidez M., Warmka J.K., Wattenberg E.V., Stack M.S., et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 61 (2001) 1855-1861
21. Arboleda M.J., Lyons J.F., Kabbinavar F.F., Bray M.R., Snow B.E., Ayala R., et al. Overexpression of AKT2/protein kinase bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63 (2003) 196-206
22. Mita M.M., Mita A., and Rowinsky E.K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer 4 (2003) 126-137
23. Chalhoub N., and Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. (2008)
24. Punt C.J., Boni J., Bruntsch U., Peters M., and Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann. Oncol. 14 (2003) 931-937
25. Raymond E., Alexandre J., Faivre S., Vera K., Materman E., Boni J., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22 (2004) 2336-2347
26. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22 (2004) 909-918
27. O'Donnell A., Faivre S., Burris H.A., Rea D., Papadimitrakopoulou V., Shand N., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 26 (2008) 1588-1595
28. Yap T.A., Carden C.P., and Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 9 (2009) 167-181
29. Aguirre D., Boya P., Bellet D., Faivre S., Troalen F., Benard J., et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9 (2004) 797-805
30. Gao N., Flynn D.C., Zhang Z., Zhong X.S., Walker V., Liu K.J., et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell. Physiol. 287 (2004) C281-C291
31. Shi Y., Frankel A., Radvanyi L.G., Penn L.Z., Miller R.G., and Mills G.B. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 55 (1995) 1982-1988
32. Hu P., Margolis B., Skolnik E.Y., Lammers R., Ullrich A., and Schlessinger J. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol. Cell. Biol. 12 (1992) 981-990
33. Jiang H.Y., and Feng Y.J. Inhibition of hypoxia-inducible factor 1alpha expression and tumor growth in SKOV3 ovarian cancer model by sirolimus. Zhonghua Fu Chan Ke Za Zhi 39 (2004) 474-477
34. Xing D., and Orsulic S.A. genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6936-6941
35. Huynh H., Teo C.C., and Soo K.C. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol. Cancer Ther. 6 (2007) 2959-2966
36. Mabuchi S., Altomare D.A., Cheung M., Zhang L., Poulikakos P.I., Hensley H.H., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin. Cancer Res. 13 (2007) 4261-4270
37. Mabuchi S., Altomare D.A., Connolly D.C., Klein-Szanto A., Litwin S., Hoelzle M.K., et al. RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 67 (2007) 2408-2413
38. Wang L.H., Chan J.L., and Li W. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Int. J. Cancer 121 (2007) 157-164
39. Scully R.F., Young R.H., and Clement P.B. Tumors of the ovary, mal-developed gonads, fallopian tube, and broad ligament (1998), Armed Forces Institute of Pathology, Washington, D.C.
40. AJCC cancer staging handbook (2002), Springer Verlag, New York
41. Uttamsingh S., Zong C.S., and Wang L.H. Matrix-independent activation of phosphatidylinositol 3-kinase, Stat3, and cyclin A-associated Cdk2 is essential for anchorage-independent growth of v-ros-transformed chicken embryo fibroblasts. J. Biol. Chem. 278 (2003) 18798-18810
42. Liu D., Rutter W.J., and Wang L.H. Enhancement of transforming potential of human insulinlike growth factor 1 receptor by N-terminal truncation and fusion to avian sarcoma virus UR2 gag sequence. J. Virol. 66 (1992) 374-385
43. Guo M., Joiakim A., and Reiners Jr. J.J. Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated aryl hydrocarbon receptor transformation and CYP1A1 induction by the phosphatidylinositol 3-kinase inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). Biochem. Pharmacol. 60 (2000) 635-642
44. Hu L., Zaloudek C., Mills G.B., Gray J., and Jaffe R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res. 6 (2000) 880-886
45. Physicians' desk reference (2007), Medical Economics Co, Oradell, N.J.
46. Maira S.M., Stauffer F., Schnell C., and Garcia-Echeverria C. PI3K inhibitors for cancer treatment: where do we stand?. Biochem. Soc. Trans. 37 (2009) 265-272
47. Ohta T., Ohmichi M., Hayasaka T., Mabuchi S., Saitoh M., Kawagoe J., et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 147 (2006) 1761-1769
48. Westfall S.D., and Skinner M.K. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol. Cancer Ther. 4 (2005) 1764-1771
49. Havrilesky L.J., Elbendary A., Hurteau J.A., Whitaker R.S., Rodriguez G.C., and Berchuck A. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet. Gynecol. 85 (1995) 1007-1010
50. Cheng J.Q., Jiang X., Fraser M., Li M., Dan H.C., Sun M., et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Updat. 5 (2002) 131-146
51. Asselin E., Mills G.B., and Tsang B.K. XIAP regulates akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61 (2001) 1862-1868
52. Page C., Lin H.J., Jin Y., Castle V.P., Nunez G., Huang M., et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 20 (2000) 407-416
53. Yang X., Fraser M., Moll U.M., Basak A., and Tsang B.K. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 66 (2006) 3126-3136
54. Hu L., Hofmann J., Lu Y., Mills G.B., and Jaffe R.B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62 (2002) 1087-1092
55. Aissat N., Le Tourneau C., Ghoul A., Serova M., Bieche I., Lokiec F., et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother. Pharmacol. 62 (2008) 305-313
56. Grant S. Cotargeting survival signaling pathways in cancer. J. Clin. Invest. 118 (2008) 3003-3006